On May 13, 2020, the launch meeting of the China Lung Cancer Rare Mutual Collaboration Group was held online, marking the official establishment of China's first lung cancer rare mutation collaborative group. Rare Occurring Mutation Alliance (ROMA) under the guidance of China Anti-Cancer Association and China Clinical Oncology Association (CSCO), together with clinicians, pathologists, joint diagnostic and testing companies and pharmaceutical companies, focuses on lung cancer The current status of rare mutation diagnosis and treatment aims to create a complete ecological closed loop through an innovative cooperation model, provide an academic exchange platform for rare targets, promote testing standards, strengthen scientific research cooperation, and benefit a series of care projects such as patient education, testing assistance, and medication assistance. Thousands of patients with rare mutations.
Professor Zhang Li, the co-founder of the Collaborative Group on Rare Mutations of Lung Cancer in China and Sun Yat-sen University ’s Cancer Prevention Center, said that the treatment of lung cancer is changing with each passing day, and precision medicine has developed rapidly in recent years. The second-generation sequencing technology has been widely used in clinical practice and more and more patients are being tested There is a rare genetic mutation, but there is not enough treatment and treatment information. It is also based on this situation that the China Lung Cancer Rare Mutual Collaboration Group was established. The collaboration group hopes to share the latest treatment progress and case information of rare mutations with colleagues to discuss how to bring better treatment to rare mutation patients.
"Rare patients" under large cancer populations
According to the national cancer statistics released by the National Cancer Center in January 2019, the number of lung cancer cases in China is 784,000, which is the largest cancer in China. Non-small cell lung cancer is the most common type of lung cancer, accounting for about 85% of the total number of lung cancer patients. With the rapid development of precise treatment of lung cancer, more and more lung cancer targeting has been approved for listing, bringing more and better choices for the treatment of patients.
However, compared with EGFR, ALK, and ROS1, which have corresponding target drugs, the current status of rare targets c-Met, Her-2, RET is not satisfactory. To treat medication. Patients with rare mutations at the corresponding targets have also become "rare patients" in large cancer populations, and new treatment drugs and social attention are urgently needed.
The results of clinical research are gratifying, patients with rare mutations welcome new hope
Among rare mutation genes, MET mutation is one of the rare mutations typical of lung cancer patients. In non-small cell lung cancer, patients with MET mutations have a poor prognosis and are insensitive to existing standard treatments. The overall survival (OS) of traditional chemotherapy is only half a year.
In recent years, there have been many studies on c-Met, a rare target, but not many have achieved brilliant breakthroughs. Recently, with the progress of basic and clinical research, and new exciting research results, c-Met The development of targeted drugs has once again gained industry attention.
Several clinical trials for MET mutations are currently underway. Among them, "the study of voritinib in the treatment of MET exon 14 transitional lung sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC)" is an open-label, single-arm, multiple Center Phase II clinical trial. The results of the Phase II study have been published and the initial effective rate is more than 50%. Such results bring hope for survival for patients with lung cancer caused by MET mutation.
The field of rare mutations needs more attention and more resources integration and investment. The establishment of the China Lung Cancer Rare Mutual Collaboration Group is conducive to the integration of rare mutation diagnosis and treatment resources in the industry, mobilizing the detection of companies, pharmaceutical companies, social groups, and doctors and other parties, focusing on the advantages of production, education and research, improving the level of rare mutation treatment and promoting more new drugs Development. At the same time, it will help to attract the community's attention to rare mutation patients, optimize the closed loop of the complete ecological chain of diagnosis and treatment, attract more R & D investment, establish and improve the rare mutation collaborative diagnosis and treatment network, promote the standardized detection and scientific treatment of rare mutation patients, Protect the health rights and interests of patients with rare mutations and contribute to building a healthy China 2030.